首页> 外文期刊>The Journal of Urology >Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study.
【24h】

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study.

机译:睾丸切除术和外部放疗联合单独放疗用于伴或不伴盆腔淋巴结转移的非转移性前列腺癌:一项前瞻性随机研究。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: We compare the combination of orchiectomy and radiotherapy to radiotherapy alone as treatment for pelvic confined prostate cancer, that is T1-4, pN0-3, M0 (TNM classification). MATERIALS AND METHODS: In this prospective study 91 patients with clinically localized prostate cancer were, after surgical lymph node staging, randomized to receive definitive external beam radiotherapy (46) or combined orchiectomy and radiotherapy (45). Patients treated with radiotherapy alone had androgen ablation at clinical disease progression. The effects on progression-free, disease specific and overall survival rates were calculated. RESULTS: After a median followup of 9.3 years (range 6.0 to 11.4) clinical progression was seen in 61% of the radiotherapy only patients (group 1) and in 31% of the combined treatment patients (group 2) (p = 0.005). The mortality was 61 and 38% (p = 0.02), and cause specific mortality was 44 and 27%, respectively (p = 0.06), in groups 1 and 2. The differences in favor of combined treatment were mainly caused by lymph node positive tumors. For node negative tumors there was no significant difference in survival rates. CONCLUSIONS: The progression-free, disease specific and overall survival rates for patients with prostate cancer and pelvic lymph node involvement are significantly better after combined androgen ablation and radiotherapy than after radiotherapy alone. These results strongly suggest that early androgen deprivation is better than deferred endocrine treatment for these patients.
机译:目的:我们比较睾丸切除术和放疗与单纯放疗作为盆腔局限性前列腺癌的治疗方法,即T1-4,pN0-3,M0(TNM分类)的比较。材料与方法:在这项前瞻性研究中,对91例临床上局限性前列腺癌的患者,在手术淋巴结分期后,随机接受了明确的体外束放疗(46)或睾丸切除和放疗联合治疗(45)。单独接受放射治疗的患者在临床疾病进展时进行了雄激素消融。计算了对无进展,疾病特异性和总生存率的影响。结果:中位随访9.3年(范围6.0至11.4)后,仅61%的放疗患者(组1)和31%的联合治疗患者(组2)观察到了临床进展(p = 0.005)。在第1组和第2组中,死亡率分别为61%和38%(p = 0.02),引起的特定死亡率分别为44%和27%(p = 0.06)。赞成联合治疗的差异主要是由于淋巴结阳性肿瘤。对于淋巴结阴性肿瘤,生存率无显着差异。结论:联合雄激素消融和放疗后,前列腺癌和盆腔淋巴结受累患者的无进展,疾病特异性和总生存率明显优于单独放疗后。这些结果强烈表明,对于这些患者,早期雄激素剥夺优于延迟内分泌治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号